Pain Therapies Market Players Exhibit Keen Interest in Chronic Neuropathic Pain Treatment, Heralding New Deal Landscape - By MRRSE
The deal and co-development landscape of the pain therapies market has been meticulously assessed; critical changes in the licensing environment are also reviewed.
Albany, NY, June 20, 2015 --(PR.com)-- Market Research Reports Search Engine (MRRSE), announces the addition of a new report titled ‘Frontier Pharma: Pain - Identifying and Commercializing First-in-Class Innovation’ to its database. The report, published by MRRSE, offers a brief introduction to pain and its various subtypes before offering a lowdown on the treatment algorithms and pharmacotherapy for the indication. Besides other important facets of the pain market, the report also discusses how the molecular target landscape has witnessed a change. The most important aspects of innovation have been investigated further to help analysts emerge with specific details about the stage of development of these therapies, the molecular target and molecule type.
Browse Full Report With TOC: http://www.mrrse.com/frontier-pharma-pain
The deal and co-development landscape of the pain therapies market has been meticulously assessed; critical changes in the licensing environment are also reviewed.
According to the findings of the report, the active pain pipeline is composed of as many as 796 products at all development stages. This gives evidence of the highly diverse array of molecular targets that are present in the active pain pipeline. The report identifies 122 first-in-class active-stage development programs. These programs account for about 13.6% of the entire pipeline, demonstrating the high degree of innovation that exists within the active pain pipeline.
The pain therapeutics market, on the other hand, presents a divergent picture. A paltry rate of innovation has been reported from the pain therapeutics market over the last decade because of the continued dominance of traditional active pharmaceutical ingredients.
Opioids dominate the segment for moderate-to-severe pain. But their potential for abuse has prompted pharmacos to reformulate opioids into abuse-resistant version. In the mild pain treatment segment, non-steroidal anti-inflammatory drugs (NSAID) enjoy a leading position. However, these drugs do not provide adequate treatment for certain types of chronic pain and neuropathic subtypes.
While most first-in-class innovation programs in the active pain pipeline still fall within the limits of early-stage development, the majority of these programs are centered on novel molecular targets for neuropathic pain – the most incapacitating and complex variety of chronic pain. Market players focusing on these drug classes could possibly alter the course of the pain therapies market.
Request Send An Enquiry: http://www.mrrse.com/enquiry/108
The pain deals ecosystem has been abuzz with several licensing and development agreements being signed over the last decade. The report finds that during this period, 112 co-development and 261 licensing agreements were signed. Despite investment dollars being channeled into the pain therapies market, there has been a conspicuous lack of deals and agreements for first-in-class products. Going forward, the unmet need for therapies to treat chronic pain and breakthroughs in research related to pathophysiologies of pain-subtypes will help foster more licensing and co-development partnerships.
About Us
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. Headquartered in New York, U.S., MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
Contact
Mr. Nachiket
State Tower
90, State Street
Suite 700
Albany, NY - 12207
United States
Telephone: +1-518-618-1030
Email: sales@mrrse.com
Website: http://www.mrrse.com/
Blog: http://industry-research-reports.blogspot.com/
Browse Full Report With TOC: http://www.mrrse.com/frontier-pharma-pain
The deal and co-development landscape of the pain therapies market has been meticulously assessed; critical changes in the licensing environment are also reviewed.
According to the findings of the report, the active pain pipeline is composed of as many as 796 products at all development stages. This gives evidence of the highly diverse array of molecular targets that are present in the active pain pipeline. The report identifies 122 first-in-class active-stage development programs. These programs account for about 13.6% of the entire pipeline, demonstrating the high degree of innovation that exists within the active pain pipeline.
The pain therapeutics market, on the other hand, presents a divergent picture. A paltry rate of innovation has been reported from the pain therapeutics market over the last decade because of the continued dominance of traditional active pharmaceutical ingredients.
Opioids dominate the segment for moderate-to-severe pain. But their potential for abuse has prompted pharmacos to reformulate opioids into abuse-resistant version. In the mild pain treatment segment, non-steroidal anti-inflammatory drugs (NSAID) enjoy a leading position. However, these drugs do not provide adequate treatment for certain types of chronic pain and neuropathic subtypes.
While most first-in-class innovation programs in the active pain pipeline still fall within the limits of early-stage development, the majority of these programs are centered on novel molecular targets for neuropathic pain – the most incapacitating and complex variety of chronic pain. Market players focusing on these drug classes could possibly alter the course of the pain therapies market.
Request Send An Enquiry: http://www.mrrse.com/enquiry/108
The pain deals ecosystem has been abuzz with several licensing and development agreements being signed over the last decade. The report finds that during this period, 112 co-development and 261 licensing agreements were signed. Despite investment dollars being channeled into the pain therapies market, there has been a conspicuous lack of deals and agreements for first-in-class products. Going forward, the unmet need for therapies to treat chronic pain and breakthroughs in research related to pathophysiologies of pain-subtypes will help foster more licensing and co-development partnerships.
About Us
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. Headquartered in New York, U.S., MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
Contact
Mr. Nachiket
State Tower
90, State Street
Suite 700
Albany, NY - 12207
United States
Telephone: +1-518-618-1030
Email: sales@mrrse.com
Website: http://www.mrrse.com/
Blog: http://industry-research-reports.blogspot.com/
Contact
MRRSE
Rananjay Parmar
+1-518-618-1030
www.mrrse.com
State Tower
90, State Street
Suite 700
Albany, NY - 12207
United States
Email : sales@mrrse.com
Rananjay Parmar
+1-518-618-1030
www.mrrse.com
State Tower
90, State Street
Suite 700
Albany, NY - 12207
United States
Email : sales@mrrse.com
Contact
Categories